sirtris

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Glaxo Makes Like Ponce de Leon With Sirtris Buy

You can't fault GlaxoSmithKline for temerity. The U.K. drugmaker's unexpectedly large $720 million bid for Sirtris Pharmaceuticals represents a gutsy bet that the Massachusetts biotech really has a handle on a class of drugs that slow aging. Not that anyone at either company is eager to describe their work that...

Tags: Pharmaceutical Company, Drug, Glaxo, Sirtris, Biotechnology, Federal Government, Government, David P. Hamilton

Blog posts 2008-04-22

Additional Resources

GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development

LONDON, PHILADELPHIA and CAMBRIDGE, Mass., June 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it has completed its acquisition of Sirtris Pharmaceuticals, Inc. Sirtris for approximately USD720 million (or approx. GBP362 million) through a cash tender offer and merger of USD22.50 (or approx. GBP11.33) per share. Through...

Articles 2008-06-06

Sirtris Pharmaceuticals Presents at the American Diabetes Association's 68th Annual Scientific Sessions June 8

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Diabetes Association's 68th Annual Scientific Sessions in San Francisco. Peter...

Articles 2008-06-04

Sirtris to become a subsidiary of GSK

Business News IN BRIEF *Fountain Acquisition Corp-oration FAC, a subsidiary of GlaxoSmithKline, has completed the tender offer for the US-based Sirtris Pharmaceuticals. The tender, worth about 362m, will see GSK take control of the Nasdaq-listed biotechnology group that specialises in developing drugs to fight age-related conditions such...

Articles 2008-06-03

GlaxoSmithKline Successfully Completes Tender Offer for Shares of Sirtris Pharmaceuticals

LONDON and PHILADELPHIA, June 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc announced today the successful completion of the tender offer by its wholly-owned subsidiary Fountain Acquisition Corporation FAC for shares of common stock of Sirtris Pharmaceuticals, Inc. . The depositary for the offer has advised GSK and FAC...

Articles 2008-06-02

Mergent, Inc. Announces Changes to the HealthShares™ Metabolic-Endocrine Disorders Index

NEW YORK, June 2 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the following changes effective on the opening of trading on Thursday, June 5, 2008: NeuroSearch AS (Copenhagen: NEUR) will replace Sirtris...

Articles 2008-06-02

GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals

LONDON, May 2 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc GSK announced today that Fountain Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Sirtris Pharmaceuticals, Inc. Sirtris, for $22.50 in cash without interest and less any required...

Articles 2008-05-02

Sirtris Pharmaceuticals Reports First Quarter 2008 Financial Results

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that it reported its consolidated financial results for the quarter ended March 31, 2008. First Quarter 2008 Financial Results Unaudited ...

Articles 2008-05-01

Bio-IT World Announces Winners of Its 2008 Best Practices Awards

Bio-IT World magazine today announced thewinners of its fourth Best Practices Awards program. Grand Prize winnerswithin seven life sciences awards categories include Applied Biosystems,Christian-Albrechts-University, Eli Lilly & Company, GlaxoSmithKline,Genstruct, Sirtris Pharmaceuticals, AstraZeneca, and Merck & Company. Established in 2003, Bio-IT World's Best Practices Awards Programrecognizes these organizations for their...

Articles 2008-04-30

Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award

Causal Network Modeling Provides Powerful Approach to Modeling Complex Biological Systems for Type 2 Diabetes CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration...

Articles 2008-04-30

Hercules Technology Expects Realized Gain from the Announced Acquisition of Sirtris Pharmaceuticals, Inc. by GlaxoSmithKline

Realized gain underlines Hercules' continued liquidity amid uncertain market conditions PALO ALTO, Calif. -- Hercules Technology Growth Capital, Inc. (NASDAQ:HTGC), the premier specialty finance company providing venture debt and equity to venture capital and private equity backed technology and life science companies at all stages of development, today...

Articles 2008-04-24

Glaxo in $720m deal for US enzyme research biotech

Business News IN BRIEF *GlaxoSmithKline, the UK's biggest drug maker, is paying $720m for an early-stage US biotech company that promises to unlock the secrets of ageing. Sirtris Pharmaceuticals, based in Cambridge, Massachusetts, is working on sirtuins, a recently discovered type of enzyme linked to the ageing...

Articles 2008-04-23

BellwetherReport.com Initiates Analyst Coverage on BRCM, ANAD, SIRT and REST

BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have scheduled interviews with a number of...

Articles 2008-04-23

GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in 'Sirtuin' Research and Development

LONDON, PHILADELPHIA AND CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- GlaxoSmithKline and Sirtris Pharmaceuticals Incorporated announced today that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50...

Articles 2008-04-22

Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics

Clinical Trial Further Demonstrates Efficacy of SIRT1 Activation In Humans CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, today announced positive top-line data from its twice-daily dosing...

Articles 2008-04-17

Sirtris Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that a research team led by the company's two Scientific Advisory Board co-chairs has demonstrated that overexpression of the SIRT1 enzyme can suppress tumor formation...

Articles 2008-04-16

Sirtris Receives Orphan Drug Designation from U.S. Food and Drug Administration for Resveratrol in Mitochondrial Disorder, MELAS Syndrome

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that the United States Food and Drug Administration has granted the company orphan-drug designation for resveratrol in the treatment of MELAS syndrome (Mitochondrial myopathy, encephalopathy,...

Articles 2008-04-02

Sirtris Pharmaceuticals Presents at American Chemical Society April 7

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced that it will be presenting at the American Chemical Society annual meeting in New Orleans on Monday, April 7 at...

Articles 2008-04-01

Sirtris Pharmaceuticals Scientific Advisor Shows SIRT1 Activation Improves Huntington's Disease In Preclinical Model

Presentations Will Take Place at the Pasteur Institute, March 28 and the British Societies for Cell and Developmental Biology at the University of Warwick, March 31 CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases...

Articles 2008-03-28

Sirtris Pharmaceuticals Announces the Appointment of Paul A. Friedman, M.D., President and CEO of Incyte Corporation, to its Board of Directors

CAMBRIDGE, Mass. -- Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Paul A. Friedman, M.D., President and CEO of Incyte Corporation, has been appointed to its Board of Directors....

Articles 2008-03-25